Trial · NCT03630588
Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity
NCT03630588, Phase 2, Completed, Technological Centre of Nutrition and Health, Spain
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity. Trials, record NCT03630588. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03630588
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity
- NCT number
- NCT03630588
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- Technological Centre of Nutrition and Health, Spain
- Conditions
- Obesity, Abdominal
- Interventions
- Surimi intervention, Placebo
- First posted
- 2018-08-15
- Last updated
- 2022-03-02
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in abdominal visceral fat (measured in mm2) | 12 weeks, week 1 and week 12 | measured by magnetic resonance imaging (MRI), transverse body scan in one axial slice 5 cm over L5-S1. |
| Secondary | Changes in parameters of body composition (weight, measured in kg) | 12 weeks, week 1 and week 12 | Trained dieticians measure weight using a body composition analyzer (Tanita SC 330-S; Tanita Corp., Barcelona, Spain). |
| Secondary | Changes in parameters of body composition (height, measured in meters) | 12 weeks, week 1 | Trained dieticians measure height using a well mounted stadiometer (Tanita Leicester Portable; Tanita Corp., Barcelona, Spain) |
| Secondary | Changes in parameters of body composition (BMI) | 12 weeks, week 1 and week 12 | Body mass index (BMI) is calculated as the ratio between measured weight (kg)/and the square of height (m). |
| Secondary | Changes in parameters of body composition (waist circumference, measured in centimeters) | 12 weeks, week 1 and week 12 | Waist circumference (WC) is measured at the umbilicus using a 150 cm anthropometric steel measuring tape. |
| Secondary | Changes in blood pressure (measured in mmHg) | 12 weeks, week 1 and week 12 | Systolic and diastolic blood pressure (SBP and DBP) are measured twice after 2-5 minutes of patient respite, seated, with one-minute interval in between, using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain). |
| Secondary | Changes in plasmatic parameters (glucose, total cholesterol, LDL and HDL cholesterol, triglycerides, non-esterified fatty acids, Apo B100, Apo A1 and Insulin, measured in mg/dL) | 12 weeks, week 1 and week 12 | Serum lipids and apolipoproteins, non-esterified fatty acids, glucose, and insulin concentrations are measured in serum by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland). LDL-c is calculated by the Friedewald formula. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35643872 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03630588
GET https://conductscience.org/api/trials/v1/NCT03630588/registered